Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Antibiotic Stewardship Biomarkers Market

ID: MRFR/Pharma/25209-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Global Antibiotic Stewardship Biomarkers Market Research Report: Size, Share, Trend Analysis By Biomarker Type (Molecular Biomarkers, Microbiological Biomarkers, Host Response Biomarkers, Pharmacokinetic/Pharmacodynamic Biomarkers, Imaging Biomarkers), By Applications (Diagnosis of Bacterial Infections, Prediction of Antibiotic Resistance, Optimization of Antibiotic Therapy, Monitoring of Antibiotic Exposure, Evaluation of New Antibiotic Therapies), By Indication (Urinary Tract Infections, Pneumonia, Sepsis, Meningitis, Infective Endocarditis), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Mass Spectrometry, Immunoassays, Biosensors) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Antibiotic Stewardship Biomarkers Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Biomarker Type (USD Billion)
  49.     4.1.1 Molecular Biomarkers
  50.     4.1.2 Microbiological Biomarkers
  51.     4.1.3 Host Response Biomarkers
  52.     4.1.4 Pharmacokinetic/Pharmacodynamic Biomarkers
  53.     4.1.5 Imaging Biomarkers
  54.   4.2 Healthcare, BY Application (USD Billion)
  55.     4.2.1 Diagnosis of Bacterial Infections
  56.     4.2.2 Prediction of Antibiotic Resistance
  57.     4.2.3 Optimization of Antibiotic Therapy
  58.     4.2.4 Monitoring of Antibiotic Exposure
  59.     4.2.5 Evaluation of New Antibiotic Therapies
  60.   4.3 Healthcare, BY Indication (USD Billion)
  61.     4.3.1 Urinary Tract Infections
  62.     4.3.2 Pneumonia
  63.     4.3.3 Sepsis
  64.     4.3.4 Meningitis
  65.     4.3.5 Infective Endocarditis
  66.   4.4 Healthcare, BY Technology (USD Billion)
  67.     4.4.1 Polymerase Chain Reaction (PCR)
  68.     4.4.2 Next-Generation Sequencing (NGS)
  69.     4.4.3 Mass Spectrometry
  70.     4.4.4 Immunoassays
  71.     4.4.5 Biosensors
  72.   4.5 Healthcare, BY Region (USD Billion)
  73.     4.5.1 North America
  74.       4.5.1.1 US
  75.       4.5.1.2 Canada
  76.     4.5.2 Europe
  77.       4.5.2.1 Germany
  78.       4.5.2.2 UK
  79.       4.5.2.3 France
  80.       4.5.2.4 Russia
  81.       4.5.2.5 Italy
  82.       4.5.2.6 Spain
  83.       4.5.2.7 Rest of Europe
  84.     4.5.3 APAC
  85.       4.5.3.1 China
  86.       4.5.3.2 India
  87.       4.5.3.3 Japan
  88.       4.5.3.4 South Korea
  89.       4.5.3.5 Malaysia
  90.       4.5.3.6 Thailand
  91.       4.5.3.7 Indonesia
  92.       4.5.3.8 Rest of APAC
  93.     4.5.4 South America
  94.       4.5.4.1 Brazil
  95.       4.5.4.2 Mexico
  96.       4.5.4.3 Argentina
  97.       4.5.4.4 Rest of South America
  98.     4.5.5 MEA
  99.       4.5.5.1 GCC Countries
  100.       4.5.5.2 South Africa
  101.       4.5.5.3 Rest of MEA
  102. 5 SECTION V: COMPETITIVE ANALYSIS
  103.   5.1 Competitive Landscape
  104.     5.1.1 Overview
  105.     5.1.2 Competitive Analysis
  106.     5.1.3 Market share Analysis
  107.     5.1.4 Major Growth Strategy in the Healthcare
  108.     5.1.5 Competitive Benchmarking
  109.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  110.     5.1.7 Key developments and growth strategies
  111.       5.1.7.1 New Product Launch/Service Deployment
  112.       5.1.7.2 Merger & Acquisitions
  113.       5.1.7.3 Joint Ventures
  114.     5.1.8 Major Players Financial Matrix
  115.       5.1.8.1 Sales and Operating Income
  116.       5.1.8.2 Major Players R&D Expenditure. 2023
  117.   5.2 Company Profiles
  118.     5.2.1 bioMerieux (FR)
  119.       5.2.1.1 Financial Overview
  120.       5.2.1.2 Products Offered
  121.       5.2.1.3 Key Developments
  122.       5.2.1.4 SWOT Analysis
  123.       5.2.1.5 Key Strategies
  124.     5.2.2 Thermo Fisher Scientific (US)
  125.       5.2.2.1 Financial Overview
  126.       5.2.2.2 Products Offered
  127.       5.2.2.3 Key Developments
  128.       5.2.2.4 SWOT Analysis
  129.       5.2.2.5 Key Strategies
  130.     5.2.3 Roche Diagnostics (CH)
  131.       5.2.3.1 Financial Overview
  132.       5.2.3.2 Products Offered
  133.       5.2.3.3 Key Developments
  134.       5.2.3.4 SWOT Analysis
  135.       5.2.3.5 Key Strategies
  136.     5.2.4 Abbott Laboratories (US)
  137.       5.2.4.1 Financial Overview
  138.       5.2.4.2 Products Offered
  139.       5.2.4.3 Key Developments
  140.       5.2.4.4 SWOT Analysis
  141.       5.2.4.5 Key Strategies
  142.     5.2.5 Siemens Healthineers (DE)
  143.       5.2.5.1 Financial Overview
  144.       5.2.5.2 Products Offered
  145.       5.2.5.3 Key Developments
  146.       5.2.5.4 SWOT Analysis
  147.       5.2.5.5 Key Strategies
  148.     5.2.6 Cepheid (US)
  149.       5.2.6.1 Financial Overview
  150.       5.2.6.2 Products Offered
  151.       5.2.6.3 Key Developments
  152.       5.2.6.4 SWOT Analysis
  153.       5.2.6.5 Key Strategies
  154.     5.2.7 Hologic (US)
  155.       5.2.7.1 Financial Overview
  156.       5.2.7.2 Products Offered
  157.       5.2.7.3 Key Developments
  158.       5.2.7.4 SWOT Analysis
  159.       5.2.7.5 Key Strategies
  160.     5.2.8 Becton Dickinson (US)
  161.       5.2.8.1 Financial Overview
  162.       5.2.8.2 Products Offered
  163.       5.2.8.3 Key Developments
  164.       5.2.8.4 SWOT Analysis
  165.       5.2.8.5 Key Strategies
  166.     5.2.9 GenMark Diagnostics (US)
  167.       5.2.9.1 Financial Overview
  168.       5.2.9.2 Products Offered
  169.       5.2.9.3 Key Developments
  170.       5.2.9.4 SWOT Analysis
  171.       5.2.9.5 Key Strategies
  172.   5.3 Appendix
  173.     5.3.1 References
  174.     5.3.2 Related Reports
  175. 6 LIST OF FIGURES
  176.   6.1 MARKET SYNOPSIS
  177.   6.2 NORTH AMERICA MARKET ANALYSIS
  178.   6.3 US MARKET ANALYSIS BY BIOMARKER TYPE
  179.   6.4 US MARKET ANALYSIS BY APPLICATION
  180.   6.5 US MARKET ANALYSIS BY INDICATION
  181.   6.6 US MARKET ANALYSIS BY TECHNOLOGY
  182.   6.7 CANADA MARKET ANALYSIS BY BIOMARKER TYPE
  183.   6.8 CANADA MARKET ANALYSIS BY APPLICATION
  184.   6.9 CANADA MARKET ANALYSIS BY INDICATION
  185.   6.10 CANADA MARKET ANALYSIS BY TECHNOLOGY
  186.   6.11 EUROPE MARKET ANALYSIS
  187.   6.12 GERMANY MARKET ANALYSIS BY BIOMARKER TYPE
  188.   6.13 GERMANY MARKET ANALYSIS BY APPLICATION
  189.   6.14 GERMANY MARKET ANALYSIS BY INDICATION
  190.   6.15 GERMANY MARKET ANALYSIS BY TECHNOLOGY
  191.   6.16 UK MARKET ANALYSIS BY BIOMARKER TYPE
  192.   6.17 UK MARKET ANALYSIS BY APPLICATION
  193.   6.18 UK MARKET ANALYSIS BY INDICATION
  194.   6.19 UK MARKET ANALYSIS BY TECHNOLOGY
  195.   6.20 FRANCE MARKET ANALYSIS BY BIOMARKER TYPE
  196.   6.21 FRANCE MARKET ANALYSIS BY APPLICATION
  197.   6.22 FRANCE MARKET ANALYSIS BY INDICATION
  198.   6.23 FRANCE MARKET ANALYSIS BY TECHNOLOGY
  199.   6.24 RUSSIA MARKET ANALYSIS BY BIOMARKER TYPE
  200.   6.25 RUSSIA MARKET ANALYSIS BY APPLICATION
  201.   6.26 RUSSIA MARKET ANALYSIS BY INDICATION
  202.   6.27 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
  203.   6.28 ITALY MARKET ANALYSIS BY BIOMARKER TYPE
  204.   6.29 ITALY MARKET ANALYSIS BY APPLICATION
  205.   6.30 ITALY MARKET ANALYSIS BY INDICATION
  206.   6.31 ITALY MARKET ANALYSIS BY TECHNOLOGY
  207.   6.32 SPAIN MARKET ANALYSIS BY BIOMARKER TYPE
  208.   6.33 SPAIN MARKET ANALYSIS BY APPLICATION
  209.   6.34 SPAIN MARKET ANALYSIS BY INDICATION
  210.   6.35 SPAIN MARKET ANALYSIS BY TECHNOLOGY
  211.   6.36 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER TYPE
  212.   6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  213.   6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  214.   6.39 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
  215.   6.40 APAC MARKET ANALYSIS
  216.   6.41 CHINA MARKET ANALYSIS BY BIOMARKER TYPE
  217.   6.42 CHINA MARKET ANALYSIS BY APPLICATION
  218.   6.43 CHINA MARKET ANALYSIS BY INDICATION
  219.   6.44 CHINA MARKET ANALYSIS BY TECHNOLOGY
  220.   6.45 INDIA MARKET ANALYSIS BY BIOMARKER TYPE
  221.   6.46 INDIA MARKET ANALYSIS BY APPLICATION
  222.   6.47 INDIA MARKET ANALYSIS BY INDICATION
  223.   6.48 INDIA MARKET ANALYSIS BY TECHNOLOGY
  224.   6.49 JAPAN MARKET ANALYSIS BY BIOMARKER TYPE
  225.   6.50 JAPAN MARKET ANALYSIS BY APPLICATION
  226.   6.51 JAPAN MARKET ANALYSIS BY INDICATION
  227.   6.52 JAPAN MARKET ANALYSIS BY TECHNOLOGY
  228.   6.53 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER TYPE
  229.   6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  230.   6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  231.   6.56 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
  232.   6.57 MALAYSIA MARKET ANALYSIS BY BIOMARKER TYPE
  233.   6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION
  234.   6.59 MALAYSIA MARKET ANALYSIS BY INDICATION
  235.   6.60 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
  236.   6.61 THAILAND MARKET ANALYSIS BY BIOMARKER TYPE
  237.   6.62 THAILAND MARKET ANALYSIS BY APPLICATION
  238.   6.63 THAILAND MARKET ANALYSIS BY INDICATION
  239.   6.64 THAILAND MARKET ANALYSIS BY TECHNOLOGY
  240.   6.65 INDONESIA MARKET ANALYSIS BY BIOMARKER TYPE
  241.   6.66 INDONESIA MARKET ANALYSIS BY APPLICATION
  242.   6.67 INDONESIA MARKET ANALYSIS BY INDICATION
  243.   6.68 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
  244.   6.69 REST OF APAC MARKET ANALYSIS BY BIOMARKER TYPE
  245.   6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION
  246.   6.71 REST OF APAC MARKET ANALYSIS BY INDICATION
  247.   6.72 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
  248.   6.73 SOUTH AMERICA MARKET ANALYSIS
  249.   6.74 BRAZIL MARKET ANALYSIS BY BIOMARKER TYPE
  250.   6.75 BRAZIL MARKET ANALYSIS BY APPLICATION
  251.   6.76 BRAZIL MARKET ANALYSIS BY INDICATION
  252.   6.77 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
  253.   6.78 MEXICO MARKET ANALYSIS BY BIOMARKER TYPE
  254.   6.79 MEXICO MARKET ANALYSIS BY APPLICATION
  255.   6.80 MEXICO MARKET ANALYSIS BY INDICATION
  256.   6.81 MEXICO MARKET ANALYSIS BY TECHNOLOGY
  257.   6.82 ARGENTINA MARKET ANALYSIS BY BIOMARKER TYPE
  258.   6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION
  259.   6.84 ARGENTINA MARKET ANALYSIS BY INDICATION
  260.   6.85 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
  261.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER TYPE
  262.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  263.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  264.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
  265.   6.90 MEA MARKET ANALYSIS
  266.   6.91 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER TYPE
  267.   6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  268.   6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  269.   6.94 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
  270.   6.95 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER TYPE
  271.   6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  272.   6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  273.   6.98 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
  274.   6.99 REST OF MEA MARKET ANALYSIS BY BIOMARKER TYPE
  275.   6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION
  276.   6.101 REST OF MEA MARKET ANALYSIS BY INDICATION
  277.   6.102 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
  278.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  279.   6.104 RESEARCH PROCESS OF MRFR
  280.   6.105 DRO ANALYSIS OF HEALTHCARE
  281.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  282.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  283.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  284.   6.109 HEALTHCARE, BY BIOMARKER TYPE, 2024 (% SHARE)
  285.   6.110 HEALTHCARE, BY BIOMARKER TYPE, 2024 TO 2035 (USD Billion)
  286.   6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  287.   6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  288.   6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  289.   6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  290.   6.115 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  291.   6.116 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
  292.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  293. 7 LIST OF TABLES
  294.   7.1 LIST OF ASSUMPTIONS
  295.     7.1.1
  296.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  297.     7.2.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  298.     7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  299.     7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  300.     7.2.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  301.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  302.     7.3.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  303.     7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  304.     7.3.3 BY INDICATION, 2025-2035 (USD Billion)
  305.     7.3.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  306.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  307.     7.4.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  308.     7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  309.     7.4.3 BY INDICATION, 2025-2035 (USD Billion)
  310.     7.4.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  311.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  312.     7.5.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  313.     7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  314.     7.5.3 BY INDICATION, 2025-2035 (USD Billion)
  315.     7.5.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  316.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  317.     7.6.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  318.     7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  319.     7.6.3 BY INDICATION, 2025-2035 (USD Billion)
  320.     7.6.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  321.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  322.     7.7.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  323.     7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  324.     7.7.3 BY INDICATION, 2025-2035 (USD Billion)
  325.     7.7.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  326.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  327.     7.8.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  328.     7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  329.     7.8.3 BY INDICATION, 2025-2035 (USD Billion)
  330.     7.8.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  331.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  332.     7.9.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  333.     7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  334.     7.9.3 BY INDICATION, 2025-2035 (USD Billion)
  335.     7.9.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  336.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  337.     7.10.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  338.     7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  339.     7.10.3 BY INDICATION, 2025-2035 (USD Billion)
  340.     7.10.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  341.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  342.     7.11.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  343.     7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  344.     7.11.3 BY INDICATION, 2025-2035 (USD Billion)
  345.     7.11.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  346.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  347.     7.12.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  348.     7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  349.     7.12.3 BY INDICATION, 2025-2035 (USD Billion)
  350.     7.12.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  351.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  352.     7.13.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  353.     7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  354.     7.13.3 BY INDICATION, 2025-2035 (USD Billion)
  355.     7.13.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  356.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  357.     7.14.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  358.     7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  359.     7.14.3 BY INDICATION, 2025-2035 (USD Billion)
  360.     7.14.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  361.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  362.     7.15.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  363.     7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  364.     7.15.3 BY INDICATION, 2025-2035 (USD Billion)
  365.     7.15.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  366.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  367.     7.16.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  368.     7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  369.     7.16.3 BY INDICATION, 2025-2035 (USD Billion)
  370.     7.16.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  371.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  372.     7.17.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  373.     7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  374.     7.17.3 BY INDICATION, 2025-2035 (USD Billion)
  375.     7.17.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  376.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  377.     7.18.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  378.     7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  379.     7.18.3 BY INDICATION, 2025-2035 (USD Billion)
  380.     7.18.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  381.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  382.     7.19.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  383.     7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  384.     7.19.3 BY INDICATION, 2025-2035 (USD Billion)
  385.     7.19.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  386.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  387.     7.20.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  388.     7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  389.     7.20.3 BY INDICATION, 2025-2035 (USD Billion)
  390.     7.20.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  391.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  392.     7.21.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  393.     7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  394.     7.21.3 BY INDICATION, 2025-2035 (USD Billion)
  395.     7.21.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  396.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  397.     7.22.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  398.     7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  399.     7.22.3 BY INDICATION, 2025-2035 (USD Billion)
  400.     7.22.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  401.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  402.     7.23.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  403.     7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  404.     7.23.3 BY INDICATION, 2025-2035 (USD Billion)
  405.     7.23.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  406.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  407.     7.24.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  408.     7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  409.     7.24.3 BY INDICATION, 2025-2035 (USD Billion)
  410.     7.24.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  411.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  412.     7.25.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  413.     7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  414.     7.25.3 BY INDICATION, 2025-2035 (USD Billion)
  415.     7.25.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  416.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  417.     7.26.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  418.     7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  419.     7.26.3 BY INDICATION, 2025-2035 (USD Billion)
  420.     7.26.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  421.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  422.     7.27.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  423.     7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  424.     7.27.3 BY INDICATION, 2025-2035 (USD Billion)
  425.     7.27.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  426.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  427.     7.28.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  428.     7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  429.     7.28.3 BY INDICATION, 2025-2035 (USD Billion)
  430.     7.28.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  431.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  432.     7.29.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  433.     7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  434.     7.29.3 BY INDICATION, 2025-2035 (USD Billion)
  435.     7.29.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  436.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  437.     7.30.1 BY BIOMARKER TYPE, 2025-2035 (USD Billion)
  438.     7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  439.     7.30.3 BY INDICATION, 2025-2035 (USD Billion)
  440.     7.30.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
  441.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  442.     7.31.1
  443.   7.32 ACQUISITION/PARTNERSHIP
  444.     7.32.1

Healthcare Market Segmentation

Healthcare By Biomarker Type (USD Billion, 2025-2035)

  • Molecular Biomarkers
  • Microbiological Biomarkers
  • Host Response Biomarkers
  • Pharmacokinetic/Pharmacodynamic Biomarkers
  • Imaging Biomarkers

Healthcare By Application (USD Billion, 2025-2035)

  • Diagnosis of Bacterial Infections
  • Prediction of Antibiotic Resistance
  • Optimization of Antibiotic Therapy
  • Monitoring of Antibiotic Exposure
  • Evaluation of New Antibiotic Therapies

Healthcare By Indication (USD Billion, 2025-2035)

  • Urinary Tract Infections
  • Pneumonia
  • Sepsis
  • Meningitis
  • Infective Endocarditis

Healthcare By Technology (USD Billion, 2025-2035)

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Mass Spectrometry
  • Immunoassays
  • Biosensors

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓